enVVeno Medical Corporation NVNO
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -50.40%
- 1 year
- -49.82%
5D -0.65 (-10.12%)
- Market cap
- 3.87M
- EPS (ttm)
- -23.27
- Shares out
- 17.54M
- Forward P/E
- -2.45
- YTD return
- -50.40%
- 1-year return
- -49.82%
- 50-day average
- 3.22
- 200-day average
- 4.62
- Volume
- 7.54K
- Avg volume
- 29.69K
- Open
- 5.64
- Previous close
- 5.77
- Day's range
- 5.43 – 5.85
- 52-week range
- 5.43 – 14.67
- Beta
- 1.22
- Price target
- 18.00 (+223.2%)
Key statistics
- Enterprise value
- -3.57M
- Price / book
- 1.08
- Free cash flow
- -9.84M
- Total cash
- 48.38M
- Total debt
- 1.15M
- Return on equity
- -58.77%
- Short % of float
- 2.74%
Fundamental scorecard
5 of 25 checks passed on NVNO’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2024 | Sep 1, 2024 | 0.00 | -0.35 | — | — |
| Jul 31, 2024 | Jun 1, 2024 | 0.00 | -0.31 | — | — |
| Jul 31, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | -0.31 | — | — |
| May 8, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | 0.00 | -0.32 | — | — |
About enVVeno Medical Corporation
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- envveno.com
News
Your note
Sign in to keep a note on NVNO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALAVI HAMED | Chief Technology Officer | Sale | Mar 12, 2024 | 0 |
| BERMAN ROBERT ANDREW | Chief Executive Officer | Purchase | Dec 18, 2024 | 222,236 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Kingdon Capital Management LLC | 4.90% | 859,261 | 2.50M | Sep 29, 2024 |
| Perceptive Advisors Llc | 3.96% | 694,315 | 2.02M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 3.40% | 596,917 | 1.74M | Sep 29, 2024 |
| Vanguard Group Inc | 3.36% | 589,141 | 1.71M | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 2.42% | 425,000 | 1.24M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 1.99% | 348,263 | 1.01M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.39% | 418,536 | 1.22M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.89% | 156,171 | 454.46K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.43% | 75,500 | 219.71K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 23,984 | 69.79K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.14% | 23,879 | 69.49K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.12% | 20,487 | 59.62K | Oct 30, 2024 |
